Adaptive Biotechnologies (ADPT) Enterprise Value (2019 - 2026)

Adaptive Biotechnologies has disclosed Enterprise Value across 8 years of filings, most recently posting $3.1 billion for Q2 2026.

• In Q2 2026, Enterprise Value rose 95.2% year-over-year to $3.1 billion; the TTM figure through Jun 2026 stood at $3.1 billion (up 95.2% YoY), while the FY2025 annual figure was $2.3 billion, up 243.56% from the prior year.
• Enterprise Value came in at $3.1 billion for Q2 2026 at Adaptive Biotechnologies, up from $2.0 billion in the prior quarter.
• In the past five years, Enterprise Value ranged from a high of $3.1 billion in Q2 2026 to a low of $164.0 million in Q1 2024.
• Average Enterprise Value over 5 years is $1.1 billion, with a median of $717.0 million recorded in 2022.
• Year-over-year, Enterprise Value tumbled 88.35% in 2022 and surged 551.67% in 2025.
• Over 5 years, Enterprise Value stood at $595.1 million in 2022, then slumped by 38.77% to $364.4 million in 2023, then jumped by 81.86% to $662.6 million in 2024, then jumped by 243.56% to $2.3 billion in 2025, then surged by 35.08% to $3.1 billion in 2026.
• Per Business Quant data, the three most recent Enterprise Value figures were $3.1 billion in Q2 2026, $2.0 billion in Q1 2026, and $2.3 billion in Q4 2025.